PharmaVoice

JUNE 27, 2025

Published June 27, 2025 Meagan Parrish Lead Editor post share post print email license Justin Sullivan via Getty Images Listen to the article 7 min This audio is auto-generated. Other PrEP regimens on the market require daily oral dosages or shots every few months, but the latest version is only administered twice a year.

FDA

Pharmacy Times

JUNE 17, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Proactive strategies in oncology care enhance financial sustainability and improve patient outcomes.

Mail-Order Pharmacies

Pharmacy Times

JUNE 23, 2025

Soefje, PharmD, MBA, BCOP, during the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon. Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling.

FDA

Pharmacy Times

JUNE 17, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. The abstract was originally shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Dosage

PharmExec

AUGUST 1, 2025

New labels will include study summaries, improved dosage warnings, and information on overdose reversal agents to enhance patient and healthcare professional awareness. Today’s FDA action is a long-overdue step toward restoring honesty, accountability, and transparency to a system that betrayed the American people.” Subscribe Now!

Medication Labelling

Pharmacy Times

JULY 4, 2025

Patients with inflammatory conditions achieved similar clinical outcomes after switching from the reference adalimumab (Humira; AbbVie) to a biosimilar, according to real-world data presented at the 2025 American Society of Health-System Pharmacists Pharmacy Futures Meeting.

Specialty Pharmacies

Pharmacy Times

JUNE 27, 2025

Generics are exact chemical copies of small-molecule drugs, with identical active ingredients, strengths, dosage forms, and routes of administration. Accessed May 13, 2025. Accessed May 13, 2025. Although generics and biosimilars offer lower-cost alternatives to brand-name drugs, they are not the same. REFERENCES 1.

Compounding Pharmacies

Pharmacy Times

JULY 10, 2025

The sNDA submitted July 8, 2025, is based on a phase 3 randomized withdrawal trial involving adults with stable schizophrenia who continued treatment with lumatperone for a 26-week double-blind phase. Time to relapse was significantly delayed in the lumatperone arm compared to placebo.

FDA

Pharmacy Times

JUNE 20, 2025

Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Carlstrom, PharmD, BCOP , Joseph A. Kalis, PharmD, BCOP Key Takeaways Oncology pharmacy's complexity outpaces the generalist model, necessitating specialization for effective patient care and operational efficiency.

Compounding

Pharmacy Times

JULY 17, 2025

Despite observational evidence, causation is not established, necessitating further research on dosage effects and neurocognitive outcomes. The inconsistency underscores the need for further research, particularly prospective studies that control for dosage and assess neurocognitive outcomes over time.

Compounding Pharmacies

Pharmacy Times

JUNE 9, 2025

HME in drug manufacturing typically employs corotated twin extruders and uses heat and pressure to create solid dosage forms, dispersing the active pharmaceutical ingredient within a molten polymer matrix, and forming a solid solution or amorphous solid dispersion. Accessed May 27, 2025. May 21, 2025. Accessed May 27, 2025.

Compounding Pharmacies

Pharmacy Times

JULY 22, 2025

By incorporating a patient's genetic profile into therapeutic decision-making, pharmacists can identify optimal drug choices and dosages while minimizing the risk of adverse events (AEs). This is particularly vital in polypharmacy scenarios, where the risk of drug-drug interactions and cumulative toxicity is high.

Compounding Pharmacies

Pharmacy Times

JUNE 13, 2025

2 Vitamin D Immunity Vitamin D is a crucial hormone that supports bone health by facilitating the absorption of calcium and phosphorus, which is obtained mainly from sunlight exposure and food. Vitamin D is an accessible and inexpensive option compared to other drugs used to improve the response to chemotherapy.”

Chemotherapy

Pharmacy Times

JUNE 19, 2025

2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. Accessed January 17, 2025. With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. September 12, 2024.

Compounding

Pharmacy Times

JUNE 10, 2025

1 "[Meloxicam injection] demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," Ron Scarboro, chief executive officer at Azurity Pharmaceuticals, said in a press release. June 10, 2025. Accessed June 10, 2025. PR Newswire. Seminars in Arthritis and Rheumatism.

FDA

Pharmacy Times

JUNE 27, 2025

I recently had the opportunity to blend my own science and philosophy at the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon, presenting on psychedelic medicines in oncology and palliative care. Potential Roles of the Oncology Pharmacist My friend died of his metastatic cancer in early 2025.

Compounding Pharmacies

Pharmaceutical Commerce

JUNE 9, 2025

Image Credit: Adobe Stock Images/Artur.com Key Takeaways Sanofi is shipping Beyfortus early to ensure strong supply for the 2025–2026 RSV season and avoid past shortages. As of now, supply for this coming season matches last year’s total dosage, with production expected to continue. June 9, 2025. Accessed June 9, 2025.

Vaccines

Pharmacy Times

JULY 7, 2025

Limitations included open-label design and dosage constraints, but the multicountry approach enhanced generalizability and external validity. All patients underwent a 20-week correction period for dosage titration and Hb correction, which was followed by an 8-week evaluation for efficacy assessments.

Compounding Pharmacies

Pharmacy Times

JULY 29, 2025

3 Vitamin D and Immune Modulation in RA Immune system control and skeletal health are both significantly impacted by vitamin D. Pharmacists can play a pivotal role in guiding safe, evidence-based supplementation by recommending appropriate dosages, monitoring for interactions, and reinforcing adherence.

Immunization

PharmTech

JUNE 12, 2025

Image Credit: © Tada Images - stock.adobe.com In a June 10, 2025 update, FDA posted seven updated Warning Letters, issued between the beginning of 2025 and the present, to its online database, which stores more than 3400 such letters dating back to 2020 (1). American Behavioral Research Institute Boca Raton, Fla. –

FDA

Pharmacy Times

JULY 12, 2025

Animal studies reveal dose-dependent hepatic responses to CBD, supporting the need for cautious monitoring even at consumer-relevant dosages. Clinical trials show low-dose CBD can cause significant liver enzyme elevations in 5.6% of healthy adults, necessitating liver function monitoring.

FDA

Pharmacy Times

JUNE 16, 2025

Steqeyma provides a new dosage form and strength, enhancing treatment flexibility for young patients with chronic inflammatory conditions. 2,3 Steqeyma, which was formerly known as CT-P43, is a human IL-12 and IL-23 antagonist indicated for multiple immune-mediated diseases.

FDA

Pharmacy Times

JUNE 30, 2025

The data from an ongoing phase 1 LIMBER trial (NCT04279847) were presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago. Thus, researchers are investigating the clinical benefit of INCB057643 in combination with Janus kinase (JAK) inhibitors, a cornerstone of MF treatment.

Compounding Pharmacies

PharmTech

JUNE 10, 2025

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).

Dosage

Pharmacy Times

JUNE 18, 2025

Results will be shared at the 2025 Oncology Pharmacists Connect meeting, potentially aiding oncology pharmacists in refining treatment strategies for sAML. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Compounding Pharmacies

Pharmacy Times

JULY 18, 2025

2,3 The FDA gave 503A compounders 60 days to cease compounding, dispensing, and distributing essentially a copy of semaglutide, ie, by April 22, 2025, or until the district court’s decision on the plaintiff’s preliminary injunction motion, whichever is later. 6 API, active pharmaceutical ingredient.

Compounding

PharmTech

JUNE 24, 2025

Some companies are combining mRNA vaccines with programmed cell death protein 1 (PD-1) inhibitors to activate the immune system and elicit tumour-specific T-cell responses. cancer and vaccines), and non-immunogenic applications (e.g., protein replacement/supplementation therapy, regenerative medicine therapy, and genetic editing) (1).

Vaccines

Pharmacy Times

JUNE 16, 2025

The investigators assessed a total of 90 patients who received talquetamab at a dosage of 0.8 mg/kg once every 2 weeks plus teclistamab at a dosage of 3.0 2 As a combination therapy, talquetamab and teclistamab show significant promise in the phase 1b/2 dose escalation and expansion in the RedirecTT-1 trial (NCT04586426).

Compounding Pharmacies

PharmTech

JUNE 12, 2025

Moving and shaking The deal, approved unanimously by the boards of both companies, is expected to close in 2025, pending customary regulatory clearances and a minimum 80% share acceptance rate from CureVac shareholders—although BioNTech retains the option to reduce this threshold to 75% (1). June 12, 2025. billion (1). billion (1).

Dosage

The Thyroid Pharmacist

AUGUST 1, 2025

Benefits for the Baby Human breast milk is nutrient-rich and contains a variety of anti-inflammatory, immune-protective, and antimicrobial properties that support your baby’s immune system and reduce the risk of lower respiratory tract infections, ear infections (otitis media), and gastroenteritis. What does the research say?

Health and Personal Care Stores

Pharmacy Times

JUNE 18, 2025

Results and conclusions will be presented at the 2025 Oncology Pharmacists Connect meeting, promoting innovation and collaboration. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Compounding Pharmacies

Pharmacy Times

JULY 30, 2025

Updated June24, 2025. Accessed July 29, 2025. Updated July 29, 2025. The primary end point is PFS, with secondary outcomes including overall survival, overall response rate, and duration of response. Cancer stat facts: Female breast cancer subtypes. National Cancer Institute.

Compounding Pharmacies

Pharmacy Times

JULY 18, 2025

DOSAGE AND ADMINISTRATION The recommended dose of gepotidacin is 1500 mg orally twice daily for 5 days. Accessed April 1, 2025. March 25, 2025. Accessed April 1, 2025. Age, body weight, race, and sex have not been shown to have a clinically relevant effect on gepotidacin exposure. 1 REFERENCES 1. Prescribing information.

Compounding Pharmacies

PharmTech

JUNE 26, 2025

in Innovation Contest for Hematologic Malignancy Treatments June 26, 2025 By Patrick Lavery News Article The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies. The company said in June 2025 that it raised €11.25 June 24, 2025. million (approximately US$1.99

Dosage

PharmTech

JUNE 10, 2025

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. On June 9, 2025, Secretary of Health and Human Services Robert F. Kennedy Jr.

Vaccines

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. In patients with severe symptoms, a dosage of 30mg can be considered.

Mayo Clinic

The Thyroid Pharmacist

NOVEMBER 29, 2023

This is because I had learned about various adulterants found in supplements, how some supplement manufacturers don’t actually put the products that are on the label in the bottle, or that the dosages listed on the label may be completely different from what’s in the products. We have 270 expiring in March 2025.)

Health and Personal Care Stores